Form 4: Dexcom CFO Sells Shares to Cover Tax Obligations

Dexcom's Chief Financial Officer, Jereme M. Sylvain, sold 744 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Jereme M. Sylvain, the Executive Vice President and Chief Financial Officer of Dexcom Inc., sold 744 shares of common stock on December 16, 2024.
• The sale was executed at a price of $76.87 per share.
• This transaction was not a discretionary trade but was mandated by Dexcom's equity incentive plan to cover tax withholding obligations.
• Following the transaction, Sylvain beneficially owns 80,030 shares of Dexcom common stock.
• This total includes 47,625 unvested restricted stock units (RSUs) which vest over the next few years.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for companies to require 'sell to cover' transactions to manage tax obligations.

Comparison to Industry Standards

• Many companies use 'sell to cover' mechanisms for stock-based compensation, so this is a standard practice.
• Executive stock sales are common and are often disclosed via SEC Form 4 filings.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Dexcom, stock sale, insider trading, Form 4, Jereme M. Sylvain, tax obligations, restricted stock units, equity incentive plan